352 related articles for article (PubMed ID: 17683481)
1. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression.
Cole AR; Noble W; van Aalten L; Plattner F; Meimaridou R; Hogan D; Taylor M; LaFrancois J; Gunn-Moore F; Verkhratsky A; Oddo S; LaFerla F; Giese KP; Dineley KT; Duff K; Richardson JC; Yan SD; Hanger DP; Allan SM; Sutherland C
J Neurochem; 2007 Nov; 103(3):1132-44. PubMed ID: 17683481
[TBL] [Abstract][Full Text] [Related]
2. Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.
Watamura N; Toba J; Yoshii A; Nikkuni M; Ohshima T
J Neurosci Res; 2016 Jan; 94(1):15-26. PubMed ID: 26400044
[TBL] [Abstract][Full Text] [Related]
3. Tau-tubulin kinase 1 and amyloid-β peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models.
Ikezu S; Ingraham Dixie KL; Koro L; Watanabe T; Kaibuchi K; Ikezu T
Acta Neuropathol Commun; 2020 Feb; 8(1):12. PubMed ID: 32019603
[TBL] [Abstract][Full Text] [Related]
4. Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease.
Takata K; Kitamura Y; Nakata Y; Matsuoka Y; Tomimoto H; Taniguchi T; Shimohama S
Am J Pathol; 2009 Jul; 175(1):17-24. PubMed ID: 19497998
[TBL] [Abstract][Full Text] [Related]
5. Increased CRMP2 phosphorylation is observed in Alzheimer's disease; does this tell us anything about disease development?
Soutar MP; Thornhill P; Cole AR; Sutherland C
Curr Alzheimer Res; 2009 Jun; 6(3):269-78. PubMed ID: 19519308
[TBL] [Abstract][Full Text] [Related]
6. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice.
Liu HL; Zhao G; Zhang H; Shi LD
Behav Brain Res; 2013 Nov; 256():261-72. PubMed ID: 23968591
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β₂₅₋₃₅ induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2.
Isono T; Yamashita N; Obara M; Araki T; Nakamura F; Kamiya Y; Alkam T; Nitta A; Nabeshima T; Mikoshiba K; Ohshima T; Goshima Y
Neurosci Res; 2013 Nov; 77(3):180-5. PubMed ID: 23994236
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease.
Uchida Y; Ohshima T; Sasaki Y; Suzuki H; Yanai S; Yamashita N; Nakamura F; Takei K; Ihara Y; Mikoshiba K; Kolattukudy P; Honnorat J; Goshima Y
Genes Cells; 2005 Feb; 10(2):165-79. PubMed ID: 15676027
[TBL] [Abstract][Full Text] [Related]
9. Proteome and behavioral alterations in phosphorylation-deficient mutant Collapsin Response Mediator Protein2 knock-in mice.
Nakamura H; Takahashi-Jitsuki A; Makihara H; Asano T; Kimura Y; Nakabayashi J; Yamashita N; Kawamoto Y; Nakamura F; Ohshima T; Hirano H; Tanaka F; Goshima Y
Neurochem Int; 2018 Oct; 119():207-217. PubMed ID: 29758318
[TBL] [Abstract][Full Text] [Related]
10. CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases.
Williamson R; van Aalten L; Mann DM; Platt B; Plattner F; Bedford L; Mayer J; Howlett D; Usardi A; Sutherland C; Cole AR
J Alzheimers Dis; 2011; 27(3):615-25. PubMed ID: 21860090
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles.
Qin X; Wang Y; Paudel HK
Am J Pathol; 2017 Aug; 187(8):1828-1847. PubMed ID: 28641077
[TBL] [Abstract][Full Text] [Related]
12. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
[TBL] [Abstract][Full Text] [Related]
13. Nasal delivery of a CRMP2-derived CBD3 adenovirus improves cognitive function and pathology in APP/PS1 transgenic mice.
Qi B; Yang Y; Cheng Y; Sun D; Wang X; Khanna R; Ju W
Mol Brain; 2020 Apr; 13(1):58. PubMed ID: 32272942
[TBL] [Abstract][Full Text] [Related]
14. CD40 ligation mediates plaque-associated tau phosphorylation in beta-amyloid overproducing mice.
Laporte V; Ait-Ghezala G; Volmar CH; Ganey C; Ganey N; Wood M; Mullan M
Brain Res; 2008 Sep; 1231():132-42. PubMed ID: 18606155
[TBL] [Abstract][Full Text] [Related]
15. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.
Shukla V; Skuntz S; Pant HC
Arch Med Res; 2012 Nov; 43(8):655-62. PubMed ID: 23142263
[TBL] [Abstract][Full Text] [Related]
16. Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo.
Cole AR; Causeret F; Yadirgi G; Hastie CJ; McLauchlan H; McManus EJ; Hernández F; Eickholt BJ; Nikolic M; Sutherland C
J Biol Chem; 2006 Jun; 281(24):16591-8. PubMed ID: 16611631
[TBL] [Abstract][Full Text] [Related]
17. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
[TBL] [Abstract][Full Text] [Related]
18. [Alzheimer's disease: cellular and molecular aspects].
Octave JN; Pierrot N
Bull Acad Natl Med; 2008 Feb; 192(2):323-31; discussion 331-2. PubMed ID: 18819686
[TBL] [Abstract][Full Text] [Related]
19. Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau.
Hensley K; Kursula P
J Alzheimers Dis; 2016 Apr; 53(1):1-14. PubMed ID: 27079722
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1.
Boutajangout A; Authelet M; Blanchard V; Touchet N; Tremp G; Pradier L; Brion JP
Neurobiol Dis; 2004 Feb; 15(1):47-60. PubMed ID: 14751770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
